[ad_1]
The Institute of Public Health (ISP) ordered the preventive withdrawal of drugs for arterial hypertension specifically, those containing valsartan .
From the entity they explained that detected, thanks to the opinion of the European Medicines Agency (EMA), an impurity identified as N-nitrosodimethylamine or NDMA that could be produced by a change in the manufacturing process of the active ingredient manufactured by Zhejing Huahai Pharmaceutical Co. China, and distributed to laboratories around the world
This anomaly, reported by the ISP, also contains smoke cigar, processed foods, toiletries, among others. Although it has not been confirmed that it generates cancer, it has been described as "probably carcinogenic to humans" .
Specifically, drugs manufactured by the following laboratories will be withdrawn from circulation: Chemopharma SA, Eurofarma Chile SA, Galenicum Health Chile SpA, Laboratorio Chile SA, Laboratorios Andrómaco SA, Laboratorio Lafi Ltda, Laboratorio Recalcine SA, Mintlab Co. SA , Pharma Investi de Chile SA
Recommendations
From the ISP they pointed out that it should not be suspended treatment because it is an alert from Precaution and its suspension can generate serious hypertensive images.
They also reported that there are several alternatives, should seek advice from the doctor or chemist
In case of product change, they suggest throwing the leftovers to avoid their consumption .
[ad_2]
Source link
